Klarsen specializes in data marketing for customer winning and engagement. Thanks to its qualified data and proprietary technologies, it allows its customers to increase their marketing performance and net sales. Klarsen disposes of proprietary assets and qualified and reactive databases, in its network of partners and on its own.

Employees

Sector

IT Services & Consulting

More about the company

Quotes

Date	Price	Change	Volume
04/26/04	€0.8520	-4.27%	12,995
03/26/03	€0.8900	-2.41%	20,832
02/26/02	€0.9120	-6.94%	32,951
01/26/01	€0.9800	-1.01%	58,185
31/26/31	€0.9900	-8.76%	32,009

Real-time Euronext Paris

More quotes

Market Closed - Euronext Paris 09:25:00 04/09/2026 pm IST			5-day change	1st Jan Change
0.8520 ^EUR	-4.27%		-21.47%	-1.84%

03/11	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2025	CI
30/25/30	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2024	CI

Market Cap	28.76L 33.42L 27.06L 24.72L 46.24L 32Cr 46.37L 3.2Cr 1.24Cr 16Cr 1.26Cr 1.23Cr 52Cr	P/E 2023	3.28x	P/E 2024	-86x
Enterprise Value	39.57L 45.98L 37.23L 34.01L 63.62L 43Cr 63.79L 4.4Cr 1.71Cr 22Cr 1.73Cr 1.69Cr 72Cr	EV / Sales 2023	1.67x	EV / Sales 2024	0.82x
Free-Float	99.21%	Yield 2023 *	-	Yield 2024	-

Markets		Quality
Euronext Paris	ALKLA	Real-time
Deutsche Boerse AG	4YA	Delayed
Börse Stuttgart	4YA	Delayed
Boerse Muenchen	4YA	Real-time

03/11	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2025	CI
30/25/30	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2024	CI
16/24/16	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2024	CI
30/24/30	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2023	CI
15/24/15	Acticor Biotech Raises EUR8 Million to Fund Emergency Stroke Treatment Development	MT
07/23/07	Acticor Biotech’s Phase 2/3 Trial for Stroke Drug Combo on Track for 2024 Results	MT
27/23/27	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2023	CI
28/23/28	Klarsen Reports Earnings Results for the Full Year Ended December 31, 2022	CI
09/23/09	Acticor Biotech Secures Funding Until November After EUR12 Million Equity Raise; Stock Sinks 17%	MT
23/22/23	Acticor Biotech Seeks To Meet With US FDA Over Phase 2/3 Study Of Stroke Drug	MT
14/22/14	Twitter to shut down newsletter product Revue next year	RE
06/22/06	Acticor Biotech Wins EU Health Agency Nod For Phase 2/3 Stroke Study Design	MT
06/22/06	Klarsen Reports Earnings Results for the Half Year Ended June 30, 2022	CI

Klarsen Share Price

Stocks

ALKLA

FR0011038348

IT Services & Consulting

Valuation : Klarsen

Chart: Klarsen

Latest news : Klarsen

Press Releases : Klarsen

News in other languages : Klarsen

Quotes and Performance

Price Extremes

Managers and Directors : Klarsen

Latest insider transactions

Other IT Services & Consulting

Financials

Company Profile

Quotes

03/03	Klarsen : ALKLA information relative au nombre total de droits de vote et d'actions composant le capital	PU
25/02	Klarsen : ALKLA-Information relative au nombre de droits de vote et actions composant le capital	PU
10/12	Klarsen : ALKLA-Attribution gratuite de BSA	PU
09/12	Klarsen : ALKLA-ACTIVITE 3T2025	PU
27/11	Klarsen : ALKLA-Résultat augmentation de capital	PU

27/08	Klarsen : ALKLA – Présentation webinaire du 27/08/2026 – Support
27/08	Klarsen : Assemblée générale – 29 Septembre 2026
19/08	Bourse : série de résultats en Europe, flambée d'Unitree et puces Nvidia en Chine
18/08	Klarsen nomme un nouveau DG pour sa filiale ITL Datamarketing
18/08	Klarsen : ALKLA – Olivier Cornelis nommé Directeur Général d’ITL – 18 Août 2026

1 day	-4.27%
1 week	-21.47%
Current month	-13.94%
1 month	+42.00%
3 months	+69.05%
6 months	-20.74%
Current year	-1.84%

1 week	0.85	1.1
1 month	0.56	1.68
Current year	0.22	1.68
1 year	0.22	1.68
3 years	0.22	3.75
5 years	0.22	4.03
10 years	0.11	5.4

Manager	Title	Age	Since
Brice Gazeau CEO	Chief Executive Officer	-	-
Patrice Coffe DFI	Director of Finance/CFO	57	01/07/2008
Jean-Pierre Domingo CTO	Chief Tech/Sci/R&D Officer	-	01/01/2013

Director	Title	Age	Since
Patrice Coffe BRD	Director/Board Member	57	14/06/2010
Gérard Parrou BRD	Director/Board Member	74	27/06/2014
Frédéric Bartoli BRD	Director/Board Member	-	23/03/2011

Date	Insider	Type	Main position	Quantity	% Market Cap.
15/03/22	Parrou Julien	Buy		2,617	0.0790%
28/02/22	Julien Parrou-Duboscq	Buy	Chief Executive Officer	3,011	0.0909%
28/02/22	Julien Parrou-Duboscq	Buy	Chief Executive Officer	3,000	0.0905%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KLARSEN	-4.27%	-21.47%	-0.93%	-76.59%	32.81L
IBM	+0.08%	-0.30%	-4.97%	+58.77%	22TCr
SNOWFLAKE INC.	-5.41%	+2.80%	+51.95%	+114.65%	12TCr
ACCENTURE PLC	-3.31%	-1.52%	-26.18%	-43.03%	11TCr
TATA CONSULTANCY SERVICES LTD.	-0.69%	-1.62%	-25.57%	-32.60%	8.83TCr
RELX PLC	-2.06%	-1.95%	-25.04%	+1.39%	6.19TCr
INFOSYS LIMITED	-0.03%	-1.22%	-22.76%	-22.87%	4.85TCr
FUJITSU LIMITED	+2.77%	-0.10%	+10.20%	+110.70%	4.34TCr
NEC CORPORATION	+2.09%	-1.63%	+8.98%	+207.52%	4.1TCr
HCL TECHNOLOGIES LIMITED	-1.94%	-1.72%	-10.39%	+4.94%	3.71TCr
Average	-1.21%	-2.87%	-4.47%	+32.29%	7.73TCr
Weighted average by Cap.	-1.17%	-0.48%	-3.24%	+40.24%

	2023	2024
Net sales	50.26L 58.41L 47.29L 43.2L 80.81L 55Cr 81.03L 5.59Cr 2.17Cr 28Cr 2.19Cr 2.15Cr 91Cr	63.11L 73.34L 59.38L 54.24L 1.01Cr 69Cr 1.02Cr 7.02Cr 2.72Cr 36Cr 2.75Cr 2.69Cr 114.45Cr
Net income	27.51L 31.97L 25.88L 23.64L 44.23L 30Cr 44.35L 3.06Cr 1.19Cr 15Cr 1.2Cr 1.17Cr 50Cr	-47.76T -55.51T -44.94T -41.05T -76.8T -52.41L -77.01T -5L -2L -26.89L -2L -2L -86.62L
Net Debt	-6L -7L -6L -5L -10.2L -6.96Cr -10.23L -70.54L -27.37L -3.57Cr -27.69L -27.08L -12Cr	10.81L 12.56L 10.17L 9L 17.38L 12Cr 17.42L 1.2Cr 46.63L 6.08Cr 47.16L 46.13L 20Cr